Review Article

Split Viewer

Blood Res 2022; 57(S1):

Published online April 30, 2022

https://doi.org/10.5045/br.2022.2022033

© The Korean Society of Hematology

Update on primary plasma cell leukemia

Sung-Hoon Jung, Je-Jung Lee

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea

Correspondence to : Je-Jung Lee, M.D., Ph.D.
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun 58128, Korea
E-mail: drjejung@chonnam.ac.kr

Received: February 3, 2022; Accepted: March 24, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell neoplasm developing in 0.5?4% of patients with multiple myeloma (MM). The diagnostic criteria were recently revised from 20% to ≥5% of circulating plasma cells in peripheral blood smears. PCL is classified as primary or secondary; primary PCL is when it presents in patients with no MM. Primary PCL shows clinical and laboratory features at presentation that differ from MM and exhibits a dismal prognosis even with the use of effective agents against MM. Therefore, intensive chemotherapy should be initiated immediately after diagnosis, and autologous stem cell transplantation is recommended for transplant-eligible patients. Maintenance therapy after transplantation may reduce the rate of early relapses. We reviewed the definitions of PCL, revised diagnostic criteria, clinical features, and appropriate initial treatments for primary PCL.

Keywords Plasma cell leukemia, Diagnosis, Treatment

Article

Review Article

Blood Res 2022; 57(S1): S62-S66

Published online April 30, 2022 https://doi.org/10.5045/br.2022.2022033

Copyright © The Korean Society of Hematology.

Update on primary plasma cell leukemia

Sung-Hoon Jung, Je-Jung Lee

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea

Correspondence to:Je-Jung Lee, M.D., Ph.D.
Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun 58128, Korea
E-mail: drjejung@chonnam.ac.kr

Received: February 3, 2022; Accepted: March 24, 2022

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Plasma cell leukemia (PCL) is a rare and highly aggressive plasma cell neoplasm developing in 0.5?4% of patients with multiple myeloma (MM). The diagnostic criteria were recently revised from 20% to ≥5% of circulating plasma cells in peripheral blood smears. PCL is classified as primary or secondary; primary PCL is when it presents in patients with no MM. Primary PCL shows clinical and laboratory features at presentation that differ from MM and exhibits a dismal prognosis even with the use of effective agents against MM. Therefore, intensive chemotherapy should be initiated immediately after diagnosis, and autologous stem cell transplantation is recommended for transplant-eligible patients. Maintenance therapy after transplantation may reduce the rate of early relapses. We reviewed the definitions of PCL, revised diagnostic criteria, clinical features, and appropriate initial treatments for primary PCL.

Keywords: Plasma cell leukemia, Diagnosis, Treatment

Table 1 . Summary of prospective and retrospective studies of treatment with novel agents for primary plasma cells leukemia..

ReferencesStudy designPatients, NMedian age, yr (range)ORR/CR (%)ASCT,
N
Median PFS (mo)Median OS (mo)
Musto et al. [24]Prospective2360 (44–80)73.9/1391428
Royer et al. [23]Prospective3957 (27–71)69/102515.136.3
Nandakumar et al. [25]Retrospective6862 (34–91)90/47201323
Dhakal et al. [30]Retrospective27760 (25–77)87/1927717% at 4 yr28% at 4 yr
Mina et al. [31]Retrospective3858 (34–80)82/18282033
Gowda et al. [32]Retrospective2356 (42–71)65/13235.518.1
D’Arena et al. [22]Retrospective2962 (42–82)79/281240% at 2 yr55% at 2 yr

Blood Res
Volume 59 2024

Stats or Metrics

Share this article on

  • line

Related articles in BR

Blood Research

pISSN 2287-979X
eISSN 2288-0011
qr-code Download